A Phase 1 interventional study of MK-1167 and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a loading dose of MK-1167 or Placebo orally on day 1, followed by a once daily (QD) maintenance dose orally on days 2 to 16.
Drug: MK-1167 · Drug: Placebo
Participants receive a loading dose of MK-1167 or Placebo orally on days 1 to 3, followed by a QD maintenance dose orally on days 4 to 16.
Drug: MK-1167 · Drug: Placebo
Oral Administration
Oral Administration
Number of Participants Experiencing an Adverse Event (AE)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
Time frame: Up to approximately 41 days
Number of Participants Discontinuing Study Treatment due to an AE
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
Time frame: Up to approximately 16 days
Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the AUC0-24 of MK-1167.
Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1, 8 and 16
Maximum Concentration (Cmax) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the Cmax of MK-1167.
Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1 and 8 and up to 600 hours postdose on day 16
Concentration at 24 hours (C24) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the C24 of MK-1167.
Time frame: 24 hours postdose on days 1, 8 and 16
Time to reach maximum concentration (Tmax) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the Tmax of MK-1167.
Time frame: Predose and at designated timepoints up to 24 hours postdose on days 1 and 8 and up to 600 hours postdose on day 16
Apparent Clearance (CL/F) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the CL/F of MK-1167.
Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16
Volume of Distribution (Vz/F) of MK-1167 at Steady State after Multiple Doses
Blood samples will be collected to determine the Vz/F of MK-1167.
Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16
Apparent Half Life (t½) of MK-1167 after Multiple Doses
Blood samples will be collected to determine the t½ of MK-1167.
Time frame: Predose and at designated timepoints up to 600 hours postdose on day 16
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2023 to primary completion in May 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-1167